OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting a newly discovered antigen, the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces the signature of a strategic collaboration agreement with a renowed research group specialized in glioblastoma immunotherapy, resistance, and cancer stem cells led by Pr. Michael Weller, head of the Department of Neurology of the University Hospital of Zurich, Switzerland.
